Industry Posters (Non-CE)
Sunday, March 16
Neurocrine Biosciences, Inc.
6:40 – 6:55 pm CDT
Substantial Long-Term Improvements With Valbenazine 40 mg in Adults With Tardive Dyskinesia
Presenter: Sean C. Hinton PhD
Valbenazine, available in 3 once-daily doses (40, 60, and 80 mg) and 2 formulations (capsule, sprinkle capsule), is approved for tardive dyskinesia (TD) and Huntington’s disease chorea. Data from 3 long-term studies, which included patients who took valbenazine for >2 years, indicate substantial TD improvements with valbenazine 40 mg.
6:55 – 7:10 pm CDT
Effects of Valbenazine on Emotional Health and Psychiatric Stability in Adults With Huntington's Disease
Presenter: Sean C. Hinton PhD
In KINECT®-HD, adults with Huntington’s disease (HD)-associated chorea received once-daily valbenazine or placebo for 12 weeks. As measured by the patient-reported Huntington’s Disease Health Index (HD-HI), some aspects of emotional health improved with valbenazine among participants affected at baseline. No worsening in psychiatric symptoms or suicidality was observed with valbenazine.
7:10 – 7:25 pm CDT
Once-Daily Valbenazine Improves Chorea Across Body Regions in Adults With Huntington's Disease: Post Hoc Shift Analyses of KINECT®-HD Data
Presenter: Sean C. Hinton PhD
In KINECT®-HD, once-daily valbenazine significantly reduced chorea severity as evaluated using the UHDRS® Total Maximal Chorea (TMC) score, which comprises 7 body regions. In this post-hoc analysis, more participants had clinically meaningful improvements with valbenazine versus placebo in each body region, with statistical significance for the upper and lower extremities.
Monday, March 17
Aucta Pharmaceuticals
9:40 - 9:55 am CDT
Neither Food nor the Use of Sprinkle Delivery Impacts the Oral Bioavailability of a Novel Extended-Release (XR) Formulation of Lacosamide
Presenter: Erika Torres, PharmD, MHS, RPh, Medical Science Liaison
The pharmacokinetic (PK) investigation of lacosamide XR capsules in this study aimed to shed light on the influence of food intake and sprinkle delivery on drug absorption. Coadministration of lacosamide XR with a high-fat meal or the use of a sprinkle administration do not affect the overall exposure of lacosamide.
Eli Lilly & Company
10 - 10:15 am CDT
The Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease: Primary Outcome Results from TRAILBLAZER-ALZ 6
Presenter: Alissa C Butler, DNP, APRN, FNP-C
TRAILBLAZER-ALZ 6, a multicenter, double-blind, phase 3b study, assessing the impact of different donanemab dosing regimens on the frequency of ARIA-E in relation to amyloid reduction. The primary endpoint, significant reduction of ARIA-E risk, was met with the modified titration regimen, which had comparable pharmacodynamics to the standard regimen.